Hinge Therapeutics
Hinge Therapeutics is an early-stage biopharmaceutical company specializing in developing small-molecule therapeutics targeting traditionally undruggable or challenging protein targets for unmet medical needs. The company utilizes its proprietary Hinge Drug Discovery Platform, which integrates artificial intelligence and a unique patented methodology to design molecules that induce functional conformational changes in proteins, enabling novel drug discovery. Their platform includes target evaluation, a proprietary hinge-focused effector library, and phenotypic assays with proprietary ion image sensor technology. Hinge Therapeutics focuses on therapeutic areas including hemophilia, solid tumors (immune oncology), cardiovascular diseases, CNS disorders including Alzheimer's, rare diseases, and anti-aging. The company has an exclusive strategic partnership with Toyohashi University of Technology in Japan to commercialize ion imaging technology for drug discovery, enhancing their validation and drug development capabilities. Hinge Therapeutics is led by a team of scientific leaders with expertise in medicine, bioinformatics, computer modeling, and pharmaceutical R&D, positioning it as a promising innovator in drug discovery for difficult targets.
Hinge Therapeutics
Hinge Therapeutics is an early-stage biopharmaceutical company specializing in developing small-molecule therapeutics targeting traditionally undruggable or challenging protein targets for unmet medical needs. The company utilizes its proprietary Hinge Drug Discovery Platform, which integrates artificial intelligence and a unique patented methodology to design molecules that induce functional conformational changes in proteins, enabling novel drug discovery. Their platform includes target evaluation, a proprietary hinge-focused effector library, and phenotypic assays with proprietary ion image sensor technology. Hinge Therapeutics focuses on therapeutic areas including hemophilia, solid tumors (immune oncology), cardiovascular diseases, CNS disorders including Alzheimer's, rare diseases, and anti-aging. The company has an exclusive strategic partnership with Toyohashi University of Technology in Japan to commercialize ion imaging technology for drug discovery, enhancing their validation and drug development capabilities. Hinge Therapeutics is led by a team of scientific leaders with expertise in medicine, bioinformatics, computer modeling, and pharmaceutical R&D, positioning it as a promising innovator in drug discovery for difficult targets.